S. Turcotte

Corrigendum to “Phenylalanine derivatives as GPR142 agonists for the treatment of Type II diabetes” [Bioorg. Med. Chem. Lett. 22 (2012) 6218–6223]

J. Reagan, W. Shen, M. Lizarzaburu, 2012 .

Phenylalanine derivatives as GPR142 agonists for the treatment of type II diabetes.

Ying Zhang, Wang Shen, Yumei Xiong, 2012, Bioorganic & medicinal chemistry letters.

Discovery and in Vivo Evaluation of Macrocyclic Mcl-1 Inhibitors Featuring an α-Hydroxy Phenylacetic Acid Pharmacophore or Bioisostere.

Sean P. Brown, A. Cheng, D. Whittington, 2019, Journal of medicinal chemistry.

Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.

Ming Yu, Ryo Okuyama, J. Reagan, 2012, Bioorganic & medicinal chemistry letters.

Optimization of triazoles as novel and potent nonphlorizin SGLT2 inhibitors.

Yun Ling, M. Lizarzaburu, J. Medina, 2011, Bioorganic & medicinal chemistry letters.